Annals of African Medicine

LETTER TO THE EDITOR
Year
: 2014  |  Volume : 13  |  Issue : 3  |  Page : 142-

Dyslipidemia among HIV-infected patients


Somsri Wiwanitkit1, Viroj Wiwanitkit2,  
1 Wiwanitkit House, Bangkhae, Bangkok, Thailand
2 Joseph Ayo Babalola University, Osun State, Osogbo, Nigeria

Correspondence Address:
Somsri Wiwanitkit
Wiwanitkit House, Bangkhae, Bangkok
Thailand




How to cite this article:
Wiwanitkit S, Wiwanitkit V. Dyslipidemia among HIV-infected patients.Ann Afr Med 2014;13:142-142


How to cite this URL:
Wiwanitkit S, Wiwanitkit V. Dyslipidemia among HIV-infected patients. Ann Afr Med [serial online] 2014 [cited 2019 Dec 7 ];13:142-142
Available from: http://www.annalsafrmed.org/text.asp?2014/13/3/142/134424


Full Text

Sir,

The recent report on dyslipidemia among HIV-infected patients is very interesting. [1] Muhammad et al., concluded that "HIV-infected patients on HAART demonstrated higher prevalence of high TC while HAART naïve subject showed higher prevalence of low HDL. [1]" Indeed, the problem of dyslipidemia is well-known among the HIV-infected patients. There are many reports worldwide. For its exact pathophysiology, "HIV-related dyslipidemia is multifactorial. [2]" The important points for the general practitioners include (a) seeking for possible dyslipidemia and other metabolic disorders among HIV-infected cases is suggested, (b) closed monitoring of dyslipidemia and other metabolic disorders during the use of HAART is required and (c) continuous updating the knowledge according to the new clinical practice guideline to manage dyslipidemia and other metabolic disorders among HIV infected. [3]

References

1Muhammad S, Sani MU, Okeahialam BN. Prevalence of dyslipidemia among human immunodefi ciency virus infected Nigerians. Ann Afr Med 2013;12:24-8.
2Rodríguez-Carranza SI, Aguilar-Salinas CA. Metabolic abnormalities in patients with HIV infection. Rev Invest Clin 2004;56:193-208.
3Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep 2012;9:206-17.